By Pharmacy Practice News Staff
The FDA granted approval of a new indication for cetuximab (Erbitux, Lilly) in combination with encorafenib (Braftovi, Pfizer) for second-line treatment of adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test.
The combination was evaluated in the multicenter, randomized, active-controlled, open-label, phase 3 BEACON CRC trial of patients who had BRAF V600E–mutant metastatic CRC and had progressed after